All In Biotech

Drug Trial Radar · NCT03980938

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)

Last checked: Nov 19, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

15

Actual

Start

Jul 8, 2019

Primary completion

Oct 15, 2020

Study completion Oct 15, 2020

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
Voisin Consulting, Inc.
First posted
Jun 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).

Conditions

  • Huntington Disease

Interventions

  • neflamapimodDrug

    40 mg neflamapimod capsule

  • PlaceboOther

    matching placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Latency During the Learning Phase of Virtual Morris Water Maze Test (vMWM)Time frame: Baseline and 10 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • John Van Geest Centre for Brain Repair

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.